Boundless Bio Earnings Call Transcripts
Fiscal Year 2026
-
Boundless and Serapha will merge in an all-stock deal, with Boundless shareholders receiving a cash dividend and a minority stake in the new entity. The combined company will focus on advancing SERP-01, a promising gene editing therapy for AATD, and expects strong financial backing through 2029.
-
The company is advancing an oral degrader targeting a novel kinesin critical for ecDNA-driven cancers, with a phase I trial underway in select breast cancer subtypes. Strong preclinical data, a robust financial runway, and a disciplined focus on clinical validation underpin its strategy.
-
Oncogene amplification remains a major unmet need in cancer, addressed by targeting ecDNA biology. The phase 1 trial of BBI-940, an oral degrader of a novel kinesin, is enrolling breast cancer patients, with initial data expected this year and efficacy readouts anticipated in the first half of next year.
Fiscal Year 2025
-
Focused on ecDNA-driven cancers, the company advances a pipeline of first-in-class molecules, including BBI-940, an oral degrader targeting a novel kinesin with promising preclinical results and a first-in-human study planned for 1H 2026. Academic and pharma interest in ecDNA is accelerating.
-
The session highlighted advances in targeting ecDNA-driven cancers, with a proprietary platform identifying novel therapeutic targets and a pipeline featuring two synergistic clinical candidates and a new oral degrader. The company is well-funded, expects key clinical readouts by 2028, and is leading innovation in a rapidly emerging field.
-
Portfolio reprioritization discontinues current BBI-355 trial arms in favor of a new combination with BBI-825, supported by strong preclinical synergy and improved safety. BBI-940, a novel kinesin degrader, advances toward IND filing. Streamlined operations extend cash runway into 2028.
-
The discussion highlighted a novel approach to targeting oncogene amplification-driven cancers by exploiting ecDNA biology, with a proprietary diagnostic tool (ECHO) and a lead CHK1 inhibitor program. Preliminary clinical data and further pipeline progress, including a unique kinesin target, are expected by year-end.
Fiscal Year 2024
-
The session highlighted a precision oncology approach targeting oncogene amplifications via ecDNA, with lead programs BBI-355 and BBI-825 advancing in clinical trials. Key updates include a biomarker-driven strategy, robust diagnostic tools, and a data readout expected in the second half of 2025.
-
A precision oncology company is advancing therapies for oncogene-amplified cancers, focusing on ecDNA biology. Lead programs target replication stress and nucleotide synthesis in ecDNA-positive tumors, with ongoing clinical trials and a novel diagnostic for patient selection.
-
The conference highlighted advances in targeting ecDNA-driven cancers, including two clinical-stage oral therapies and a novel diagnostic assay with high accuracy. Combination strategies and biomarker-driven patient selection are central, with key efficacy data expected in 2025.
-
The company is pioneering therapies targeting ecDNA-driven oncogene amplification in cancer, leveraging a proprietary platform and diagnostic to address a major unmet need. Lead programs are advancing through clinical trials with strong financial backing and growing industry interest.